Nanollose Ltd (ASX: NC6) Share Price and News

Mr Willesee is a company director with over 20 years of experience in various roles within the Australian capital markets. Mr Willesee has experience with ASX listed and other companies over a broad range of industries having been involved with many successful ventures from early stage through to large capital development projects. He has expertise in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance.

Dr Best has 40 years of experience in organic chemistry both in academia, government and industry. He took up a position with ICI Australia's Research Group in Melbourne for four and a half years which included a secondment to ICI Agrochemicals in the UK. Following ICI, Wayne returned to Western Australia and spent ten years at the Chemistry Centre (WA) where he was responsible for the formation and running of the Medicinal & Biological Chemistry Section which undertook collaborative R&D into drug discovery and contract synthesis for the drug discovery and pharmaceutical industries. He then founded Epichem Pty Ltd, a contract research and drug discovery Company, which he managed for 14 years before moving full-time to Nanollose in 2018 He has served as a director for several listed and unlisted biotechnology companies.

Ms Beatty, founder of Crown Abbey Ltd is a scientist and innovator who has 20 years of experience developing consumer and health care products. After gaining a BSc in Chemistry from the University of York UK, Heidi worked with Johnson & Johnson for 10 years in Europe and the US. In 2015 Heidi founded Crown Abbey Ltd, a consultancy company that supports clients in their project launches, combining Project Management and Product Development across Consumer and Healthcare categories.

-

-